Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with primary central nervous system lymphoma (a type of lymphoma affecting the brain or spinal cord), or who have a relapsed secondary central nervous system lymphoma (a specific type called diffuse large B-cell lymphoma), confirmed by tissue testing according to recognised diagnostic guidelines.
• People who are willing and able to sign a consent form and follow the visit schedule and procedures required by the trial.
• People who have had a brain MRI scan (with and without contrast dye) within 28 days before joining the trial, showing at least one measurable area of disease.
• People with a general health and functioning level that falls within a specified range (ECOG score of 0–4, meaning anywhere from fully active to completely dependent — confirm with trial site).
• People whose blood counts, liver, kidney, heart, clotting, and thyroid function all meet minimum levels set by the trial, based on recent blood tests.
• People with a life expectancy of more than 3 months.
• People aged 18 years or older.
• People of childbearing potential, and men whose partners could become pregnant, who are willing to use effective contraception during treatment and for 90 days after the last dose.

Who may not be able to join:

• People whose lymphoma has spread to parts of the body outside the brain or spinal cord.
• People with a history of another cancer, except for certain treated and resolved cancers such as some skin cancers, superficial bladder cancer, early-stage cervical cancer, certain early gastrointestinal cancers, or breast cancer with no recurrence in the past 5 years.
• People with a history of serious allergic reactions, severe drug allergies, or known sensitivity to the type of medication used in this trial (a PD-1 monoclonal antibody injection or its components).
• People who have previously been treated with certain immune checkpoint therapies (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies) or CAR-T cell therapy.
• People who have previously received an organ transplant or a stem cell transplant from another person.
• People who are planned to receive other systemic cancer treatments during the trial.
• People who have received cancer vaccines or other immune-stimulating cancer treatments within 3 months before the first trial dose.
• People with a severe active or ongoing infection that requires systemic treatment.
• People with an active autoimmune disease, or a history of one within the past 2 years (some exceptions may apply, such as certain thyroid or skin conditions — confirm with trial site).
• People who have used immune-suppressing medications within 4 weeks before the first trial dose, with some exceptions for low-dose or locally applied steroids (confirm with trial site).
• People who test positive for HIV, have active hepatitis, or have other uncontrolled infections.
• People with a current or past history of idiopathic pulmonary fibrosis or idiopathic pneumonia (unexplained scarring or inflammation of the lungs).
• People with known active tuberculosis.
• People who have previously had a severe (grade 3 or higher) immune-related side effect from immunotherapy.
• People with a confirmed history of significant neurological or psychiatric conditions.
• People who have received a live vaccine (such as flu or chickenpox vaccines) within 4 weeks before the first dose, or who plan to receive one during the trial.
• People with a known history of alcohol or drug abuse.
• People who are pregnant or breastfeeding.
• People who have taken part in another clinical drug trial with active treatment within 1 month before the first dose.
• People with any other condition that the trial doctor believes could affect the safety or results of the trial.

Important: Always verify eligibility with the trial site directly before applying.